Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials

Androgen deprivation therapy (ADT) has been used in the treatment of metastatic prostate cancer since the first description of its hormonal dependence in 1941. In 2004, docetaxel chemotherapy became the mainstay of treatment in metastatic castration-resistant prostate cancer (mCRPC), following robus...

Descripción completa

Detalles Bibliográficos
Autores principales: van Soest, Robert J., de Wit, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687286/
https://www.ncbi.nlm.nih.gov/pubmed/26695172
http://dx.doi.org/10.1186/s12916-015-0543-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687286/
https://www.ncbi.nlm.nih.gov/pubmed/26695172
http://dx.doi.org/10.1186/s12916-015-0543-9

Ejemplares similares